Therapeutic Plasma Exchange Market By Product Type (Devices, Disposables); By Application (Neurological Disorders, Autoimmune Disorders, Hematological Disorders, Metabolic Disorders, Others); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centres); By Geography, Segment Revenue Estimation, Forecast, 2024–2032.

The global therapeutic plasma exchange market size was USD 1.5 billion in 2023 and, based on analysis, is expected to reach USD 3.1 billion in the forecast period at a CAGR of 10.2%. The market is growing due to the increasing trend of autoimmune diseases, development of plasma exchange technologies, as well as expansion of TPE applications in novel geographical regions. TPE has emerged as an essential approach in the current health practice to allow the delivery of targeted treatment with minimal side effects.

 

Therapeutic Plasma Exchange (TPE) or plasmapheresis is a technique in which the patient's plasma is removed, treated, and reinfused. This technique is popular in the treatment of almost all autoimmune and some neurological conditions, including Guillain-Barré Syndrome, Myasthenia Gravis, and thrombotic thrombocytopenic purpura. TPE is also used in severe infection, blood pathology, and organ transplantation rejection treatment.

 

Market Dynamics (Powering Progress: Key Drivers in the Therapeutic Plasma Exchange Market)

Rising Prevalence of Autoimmune Disorders: Lupus, multiple sclerosis and Guillain-Barré Syndrome are among the autoimmune diseases increasing in occurrence around the world. The NIH estimates that there were about 2.8 million people diagnosed with multiple sclerosis globally by 2023 to boost plasma exchange therapies. Example: Autoimmune diseases are on the rise in the United States of America, with 24 million cases recorded every year, and over seventy thousand patients receive plasma exchange as part of treatment.

Technological Advancements in TPE Devices: Today the critical plasma exchange devices have been enhanced with regard to the effectiveness, safety and speed of the operation. Latest technologies like automatic monitoring systems, better filtration systems and small structures have made TPE more convenient and comfortable to patients. Example: The new Fresenius Medical Care COM.TEC apheresis system is the modern device, which provides real-time plasma volume measurements during TPE, which increases the safety of the procedure.

Increasing Use in Neurological Disorders: Chronically ill autoimmune disorders like Myasthenia Gravis and chronic inflammatory demyelinating polyneuropathy have increasingly used therapeutic plasma exchange (TPE). The fact that TPE can quickly start alleviating symptoms has firmly placed it as the go-to for most conditions. According to the Myasthenia Gravis Foundation of America, about 20% of MG patients with serious symptoms receive TPE per year.

 

Untapped Potential: Growth Opportunities in the Therapeutic Plasma Exchange Market

Emerging Markets in Asia-Pacific and Latin America: Several reduced healthcare systems within the emergent economies provide greater potential for business development while the awareness regarding the plasmatic-based therapies tends to rise in the coming years. Policymakers in nations such as India and Brazil are seeking to purchase better healthcare diagnosis tools, including plasma exchange equipment. Example: Major hospitals were provided with plasma exchange units in 2023 to cater to the increasing demand due to autoimmune and blood disorders, as planned by the Indian government.

Increasing Clinical Applications: This shift has not fully been tapped into emergent clinical areas such as sepsis, organ transplantation, and oncology. The deadliness of cytokine storms that occur with severe infections such as COVID-19 has made TPE a go-to choice, given research findings showing potential in managing them. A report in the Journal of Clinical Apheresis stated that the effectiveness of cytokine release syndrome, when managed with plasma exchange was 30% higher in patient outcomes.

 

Barriers to Adoption: Challenges Facing the Therapeutic Plasma Exchange Market

High Cost of Treatment: Therapeutic plasma exchange is an expensive process and each session costs between $2500 – $5,000 in the developed world. This is due to multiple sessions, which imply a greater financial cost to the patients and the stakeholders in the health sector, particularly in the least developed areas. Example: In rural areas of Africa, the cost of TPE is still high and this means that very few people are able to get this service.

Shortage of Skilled Professionals: The procedure involves the use of complex equipment and carries the risk of complications; the procedure, therefore, demands expertise. Few people are professionally trained in this area in many parts of the world, and this has limited the application of TPE.

 

Market Segmentation

By Product Type

• Devices

• Disposables

 

By Application

• Neurological Disorders

• Autoimmune Disorders

• Hematological Disorders

• Metabolic Disorders

• Others

 

By End User

• Hospitals

• Specialty Clinics

• Ambulatory Surgical Centres

 

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

 

Segment Analysis

By Product Type

The devices segment ruled the market with 65% of total revenues in 2023. Modern plasma exchange equipment with built-in control mechanisms and advanced filters provide increased adaptability in use and added safety for their utilizers, making plasma exchange equipment popular in hospitals and clinics. The constant innovation of portable, easy-to-handle devices makes the gadgets important tools to health care professionals. Example: The major product in this segment that is worth mentioning here is Terumo BCT’s Spectra Optia Apheresis System, which has several valves lined with it.

By Application

Neurological disorders segment will register the highest growth with a compounded annual rate of 12.3% in the forecast period. TPE is gradually becoming popular to treat diseases such as Guillain-Barré Syndrome and Myasthenia Gravis since it has been seen to produce relief from symptoms. Example: Multiple researches have established that plasma exchange can shorten the time taken for patients recovering from Guillain-Barré Syndrome by 40-50 %; thus, plasma exchange is important.

By End User

Hospitals continue to dominate consumption and represented 70% of overall market revenues in 2023, owing to rich infrastructure and skilled professionals. Despite this, specialty clinics are proving to be a key segment simply because they are dealing in specific disorders and or affordable treatments.

By Region

North America also has one of the highest shares of therapeutic plasma exchange; in 2023 it accounted for 45% of total revenue. These largest share of this region is due to the high widespread presence of autoimmune diseases, better health care systems, and good reimbursement policies. Example The Mayo Clinic in the United States is one of the biggest centres for TPE procedures performing thousands of sessions per year for those with severe autoimmune and neurological diseases.

 

Key Players

• Fresenius Medical Care

• Terumo BCT

• Haemonetics Corporation

• Baxter International Inc.

• B. Braun Melsungen AG

• Asahi Kasei Medical Co., Ltd.

• Cerus Corporation

• Nikkiso Co., Ltd.

• Kawasumi Laboratories Inc.

• Miltenyi Biotec

 

Future Outlook

There is a great potential in developing therapeutic plasma exchange due to innovations in technology, the increase in new diseases, recognition of neurological autoimmune diseases, and the spread in the development markets. Promising technologies such as Artificial Intelligence based monitoring, miniaturized and portable equipment solution, integration with telemedicine are tagged to transform this industry.

The market is poised to enter new areas of market penetration by 2030, especially those centres that have not had easy access to this technology due to issues to do with cost. The factor of new entrants targeting the sectors of low costs and high efficiency will be one of the major driving forces for the market.

Therefore, it can be concluded that therapeutic plasma exchange is an emerging and developing market of the healthcare industry creating great opportunities for growth and development. Due to regional diversification, R&D investment stakeholders are well poised to benefit from the incremental growth of the market over the decade.